XML 25 R14.htm IDEA: XBRL DOCUMENT v3.26.1
SEGMENT REPORTING
 3 Months Ended
Mar. 31, 2026
SEGMENT REPORTING  
SEGMENT REPORTING

NOTE 7 – SEGMENT REPORTING

a.The Company operates in one reportable segment: clinical development. The clinical development segment facilitates the development of potential new drug compounds, and its business is unified for the purposes of valuation of its performance.

Management does not segregate its business for internal reporting. The Company's Chief Operating Decision Maker (“CODM”), who is the CEO evaluates the Company's performance based on its unified internal reporting which is consistent with the presentation in the Company’s financial statements.

Net loss is used to monitor budget versus actual results.

The CODM uses many quantitative and qualitative factors including net loss, and quarterly cash burn in benchmarking the Company to its competitors. The competitive analysis along with the monitoring of budgeted versus actual results are used in assessing performance of the segment and in establishing management’s compensation.

Significant segment expenses are presented in the Company’s statements of operations. Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company’s statements of operations, are presented below:

​

​

​

​

​

​

​

​

​

Three Months Ended March 31

​

  ​ ​ ​

2026

  ​ ​ ​

2025

R&D Employee Expenses

 

$

2,065

 

$

1,717

R&D Clinical Trial Expenses

​

​

1,212

 

​

1,036

R&D Professional Fees

​

​

—

​

​

13

R&D Manufacturing

​

​

829

​

​

476

R&D License Fees

​

​

—

​

​

438

G&A Professional Fees

​

​

1,157

​

​

957

G&A Employee Expenses

​

​

601

​

​

502

G&A Insurance and other

 

​

396

​

​

429

Other Segment Items *

 

​

(210)

 

​

(236)

Segment Loss

​

$

6,050

 

$

5,332

* - Other Segment Items included in net loss includes finance income.